172 related articles for article (PubMed ID: 14688003)
1. Thalidomide plus oral melphalan for advanced multiple myeloma: a phase II study.
Offidani M; Marconi M; Corvatta L; Olivieri A; Catarini M; Leoni P
Haematologica; 2003 Dec; 88(12):1432-3. PubMed ID: 14688003
[No Abstract] [Full Text] [Related]
2. Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial.
Hulin C; Facon T; Rodon P; Pegourie B; Benboubker L; Doyen C; Dib M; Guillerm G; Salles B; Eschard JP; Lenain P; Casassus P; Azaïs I; Decaux O; Garderet L; Mathiot C; Fontan J; Lafon I; Virion JM; Moreau P
J Clin Oncol; 2009 Aug; 27(22):3664-70. PubMed ID: 19451428
[TBL] [Abstract][Full Text] [Related]
3. Primary treatment with pulsed melphalan, dexamethasone and thalidomide for elderly symptomatic patients with multiple myeloma.
Dimopoulos MA; Anagnostopoulos A; Terpos E; Repoussis P; Zomas A; Katodritou E; Kyrtsonis MC; Delibasi S; Vassou A; Pouli A; Zervas K; Anagnostopoulos N; Maniatis A;
Haematologica; 2006 Feb; 91(2):252-4. PubMed ID: 16461313
[TBL] [Abstract][Full Text] [Related]
4. Intravenous melphalan, thalidomide and prednisone in refractory and relapsed multiple myeloma.
Palumbo A; Avonto I; Bruno B; Ambrosini MT; Bringhen S; Cavallo F; Falco P; Boccadoro M
Eur J Haematol; 2006 Apr; 76(4):273-7. PubMed ID: 16519697
[TBL] [Abstract][Full Text] [Related]
5. Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma Network.
Palumbo A; Falco P; Corradini P; Falcone A; Di Raimondo F; Giuliani N; Crippa C; Ciccone G; Omedè P; Ambrosini MT; Gay F; Bringhen S; Musto P; Foà R; Knight R; Zeldis JB; Boccadoro M; Petrucci MT;
J Clin Oncol; 2007 Oct; 25(28):4459-65. PubMed ID: 17785703
[TBL] [Abstract][Full Text] [Related]
6. Combination therapy with thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma not undergoing upfront autologous stem cell transplantation: a phase II trial.
Dingli D; Rajkumar SV; Nowakowski GS; Gertz MA; Dispenzieri A; Lacy MQ; Hayman S; Fonseca R; Lust JA; Kyle RA; Greipp PR; Witzig TE
Haematologica; 2005 Dec; 90(12):1650-4. PubMed ID: 16330438
[TBL] [Abstract][Full Text] [Related]
7. Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma.
Berenson JR; Yang HH; Sadler K; Jarutirasarn SG; Vescio RA; Mapes R; Purner M; Lee SP; Wilson J; Morrison B; Adams J; Schenkein D; Swift R
J Clin Oncol; 2006 Feb; 24(6):937-44. PubMed ID: 16418495
[TBL] [Abstract][Full Text] [Related]
8. Thalidomide-dexamethasone plus pegylated liposomal doxorubicin vs. thalidomide-dexamethasone: a case-matched study in advanced multiple myeloma.
Offidani M; Bringhen S; Corvatta L; Falco P; Marconi M; Avonto I; Piersantelli MN; Polloni C; Boccadoro M; Leoni P; Palumbo A
Eur J Haematol; 2007 Apr; 78(4):297-302. PubMed ID: 17286608
[TBL] [Abstract][Full Text] [Related]
9. Bortezomib plus melphalan and prednisone for multiple myeloma.
Avvisati G
N Engl J Med; 2008 Dec; 359(24):2613; author reply 2613-4. PubMed ID: 19090032
[No Abstract] [Full Text] [Related]
10. First-line treatment of elderly multiple myeloma patients.
Palumbo A
Clin Adv Hematol Oncol; 2010 Aug; 8(8):529-30. PubMed ID: 20966887
[No Abstract] [Full Text] [Related]
11. Oral melphalan, prednisone, and thalidomide for newly diagnosed patients with myeloma.
Palumbo A; Bertola A; Musto P; Caravita T; Callea V; Nunzi M; Grasso M; Falco P; Cangialosi C; Boccadoro M
Cancer; 2005 Oct; 104(7):1428-33. PubMed ID: 16116606
[TBL] [Abstract][Full Text] [Related]
12. Low-dose thalidomide with pegylated liposomal doxorubicin and high-dose dexamethasone for relapsed/refractory multiple myeloma: a prospective, multicenter, phase II study.
Offidani M; Corvatta L; Marconi M; Visani G; Alesiani F; Brunori M; Galieni P; Catarini M; Burattini M; Centurioni R; Rupoli S; Scortechini AR; Giuliodori L; Candela M; Capelli D; Montanari M; Olivieri A; Piersantelli MN; Leoni P
Haematologica; 2006 Jan; 91(1):133-6. PubMed ID: 16434383
[TBL] [Abstract][Full Text] [Related]
13. Post-transplant outcomes of induction therapy for myeloma: thalidomide and dexamethasone versus doxorubicin, vincristine, and dexamethasone prior to high-dose melphalan with autologous stem cell support.
Vogl DT; Liu SV; Chong EA; Luger SM; Porter DL; Schuster SJ; Tsai DE; Perl A; Loren AW; Goldstein SC; Nasta SD; Andreadis C; Mangan PA; Hummel K; Siegel DL; Glatstein E; Stadtmauer EA
Am J Hematol; 2007 Dec; 82(12):1071-5. PubMed ID: 17696204
[TBL] [Abstract][Full Text] [Related]
14. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression.
Mateos MV; Hernández JM; Hernández MT; Gutiérrez NC; Palomera L; Fuertes M; Garcia-Sanchez P; Lahuerta JJ; de la Rubia J; Terol MJ; Sureda A; Bargay J; Ribas P; Alegre A; de Arriba F; Oriol A; Carrera D; García-Laraña J; García-Sanz R; Bladé J; Prósper F; Mateo G; Esseltine DL; van de Velde H; San Miguel JF
Haematologica; 2008 Apr; 93(4):560-5. PubMed ID: 18322252
[TBL] [Abstract][Full Text] [Related]
15. Deep venous thrombosis and thalidomide therapy for multiple myeloma.
Osman K; Comenzo R; Rajkumar SV
N Engl J Med; 2001 Jun; 344(25):1951-2. PubMed ID: 11419443
[No Abstract] [Full Text] [Related]
16. Advances in the treatment of elderly patients with multiple myeloma.
Facon T
Clin Adv Hematol Oncol; 2006 Jul; 4(7):501-2. PubMed ID: 17147234
[No Abstract] [Full Text] [Related]
17. Low-dose thalidomide regimens in therapy of relapsed or refractory multiple myeloma.
Zemanova M; Scudla V; Adam Z; Gregora E; Pour L; Minarik J; Pavlicek P; Pika T; Bacovsky J
Neoplasma; 2008; 55(4):345-9. PubMed ID: 18505347
[TBL] [Abstract][Full Text] [Related]
18. Thalidomide maintenance in multiple myeloma: certainties and controversies.
Cavo M; Pantani L; Tacchetti P; Pallotti MC; Brioli A; Petrucci A; Zamagni E; Tosi P
J Clin Oncol; 2009 Nov; 27(32):e186-7; author reply e188. PubMed ID: 19770366
[No Abstract] [Full Text] [Related]
19. Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure.
Spencer A; Prince HM; Roberts AW; Prosser IW; Bradstock KF; Coyle L; Gill DS; Horvath N; Reynolds J; Kennedy N
J Clin Oncol; 2009 Apr; 27(11):1788-93. PubMed ID: 19273705
[TBL] [Abstract][Full Text] [Related]
20. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group.
Rajkumar SV; Blood E; Vesole D; Fonseca R; Greipp PR;
J Clin Oncol; 2006 Jan; 24(3):431-6. PubMed ID: 16365178
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]